| IL-18 induces PD-1–dependent immunosuppression in cancer M Terme, E Ullrich, L Aymeric, K Meinhardt, M Desbois, N Delahaye, ... Cancer research 71 (16), 5393-5399, 2011 | 411 | 2011 |
| Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors S Rusakiewicz, M Semeraro, M Sarabi, M Desbois, C Locher, R Mendez, ... Cancer research 73 (12), 3499-3510, 2013 | 344 | 2013 |
| Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer C Coutzac, JM Jouniaux, A Paci, J Schmidt, D Mallardo, A Seck, ... Nature communications 11 (1), 2168, 2020 | 323 | 2020 |
| Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer M Hornburg, M Desbois, S Lu, Y Guan, AA Lo, S Kaufman, A Elrod, ... Cancer cell 39 (7), 928-944. e6, 2021 | 205 | 2021 |
| Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 D Hannani, M Vetizou, D Enot, S Rusakiewicz, N Chaput, D Klatzmann, ... Cell research 25 (2), 208-224, 2015 | 198 | 2015 |
| Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer M Desbois, AR Udyavar, L Ryner, C Kozlowski, Y Guan, M Dürrbaum, ... Nature communications 11 (1), 5583, 2020 | 138 | 2020 |
| Cancer-induced immunosuppression: IL-18–elicited immunoablative NK cells M Terme, E Ullrich, L Aymeric, K Meinhardt, JD Coudert, M Desbois, ... Cancer research 72 (11), 2757-2767, 2012 | 134 | 2012 |
| Cancer‐associated fibroblasts: key players in shaping the tumor immune microenvironment M Desbois, Y Wang Immunological reviews 302 (1), 241-258, 2021 | 119 | 2021 |
| IL-15 trans-signaling with the superagonist RLI promotes effector/memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists M Desbois, P Le Vu, C Coutzac, E Marcheteau, C Béal, M Terme, A Gey, ... The Journal of Immunology 197 (1), 168-178, 2016 | 57 | 2016 |
| Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome N Chaput, C Flament, C Locher, M Desbois, A Rey, S Rusakiewicz, ... Oncoimmunology 2 (2), e23080, 2013 | 42 | 2013 |
| Natural killer cells in non-hematopoietic malignancies M Desbois, S Rusakiewicz, C Locher, L Zitvogel, N Chaput Frontiers in immunology 3, 395, 2012 | 41 | 2012 |
| IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: Implications for antimetastatic treatment M Desbois, C Béal, M Charrier, B Besse, G Meurice, N Cagnard, ... Journal for Immunotherapy of Cancer 8 (1), 2020 | 33 | 2020 |
| Breaking immune tolerance in cancer M Desbois, S Champiat, N Chaput Bulletin du Cancer 102 (1), 34-52, 2015 | 6* | 2015 |
| Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects J Delahousse, C Skarbek, M Desbois, JL Perfettini, N Chaput, A Paci Journal for Immunotherapy of Cancer 8 (2), 2020 | 4 | 2020 |
| Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity BT Wang, M Desbois, SE Calhoun, TJ Matthew, P Yakkundi, L Wang, ... Cancer Res. 82, 1068, 2022 | 2 | 2022 |
| Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models M Desbois, SE Calhoun, KC Hart, C Denson, P Yakkundi, TJ Matthew, ... breast 1, 10.6, 2024 | 1 | 2024 |
| IGM-7354, AN ANTI-PD-L1/IL-15 IGM IMMUNOCYTOKINE, ACTIVATES AND EXPANDS NK CELLS AND EFFECTOR MEMORY CD8 (+) T CELLS IN VIVO M Desbois, T Giffon, P Yakkundi, S Pandey, R Rosete, D Machado, ... Journal for ImmunoTherapy of Cancer 10, A1260-A1260, 2022 | 1 | 2022 |
| 711 IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion T Giffon, M Desbois, D Ng, P Yakkundi, M Manlusoc, M Oyasu, R Rosete, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A740-A740, 2021 | 1 | 2021 |
| Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity BT Wang, T Kothambawala, KC Hart, X Chen, M Desbois, SE Calhoun, ... Proceedings of the American Association for Cancer Research Annual Meeting …, 2021 | 1 | 2021 |
| Reactive stroma mediates CD8+ T cell spatial distribution and function in ovarian cancer Y Wang, L Ryner, AR Udyavar, M Desbois, C Kozlowski, CW Chang, ... Annals of Oncology 28, v349, 2017 | 1 | 2017 |
